MedComm (2020) June 2023 PMID 37250144

RAS-targeted cancer therapy: Advances in drugging specific mutations.

Cen Liu, Danyang Ye, Hongliu Yang, Xu Chen, Zhijun Su, Xia Li, Mei Ding, Yonggang Liu

Full text PDF Download social card

Mentions

Peak: 6 in May 2023

across 2 sources since May 2023

Extended reach

3,529

potential audience

Total likes

Video views

Mentions per month

May 2023 – Sep 2023

Where it's discussed

X / Twitter6 posts
YouTube1 videos

AI synopsis

What people are saying

The overall tone emphasizes the importance of the review, with comments like 'Excellent review' and phrases indicating appreciation for the insights into past, present, and future developments. The words reflect enthusiasm and acknowledgment, suggesting that the publication inspires further interest and recognition within the scientific community.

AgreementStrong agreement

All posts show strong support and positive acknowledgment of the publication, indicating consensus that the review is valuable.

InterestHigh interest

Discussions reflect a high level of curiosity and interest in the advancements and future directions of RAS-targeted therapies.

EngagementModerate engagement

While most posts express appreciation and reinforce key points, they do not deeply analyze specific details, resulting in moderate engagement.

ImpactModerate impact

Participants recognize the significance of recent progress in targeting previously 'undruggable' mutations, implying a meaningful impact on cancer treatment research.

Abstract in brief

Advances in RAS-targeted cancer therapy focus on developing specific inhibitors for RAS mutations, with recent success in targeting KRAS, which was previously considered "undruggable."
The effectiveness of KRAS inhibitors varies depending on different RAS alleles and cancer types, emphasizing the need to understand the unique features of each mutation.
The review summarizes the structural, biochemical, and clinical aspects of RAS mutations, along with current strategies for direct and indirect RAS inhibition, aiming to inspire more research into allele-specific treatments.]

Read the full abstract

All mentions

Advances in RAS-Targeted Cancer Therapies and Mutation Inhibition

Advances in RAS-targeted cancer therapy focus on developing specific inhibitors for RAS mutations, with recent success in targeting KRAS, which was previously considered "undruggable."

Medicine RTCL TV · Sep 16, 2023 41 views

C Faith

@Abbeyandsmokey · X

RT @CrozrX: RAS-targeted cancer therapy: Advances in drugging specific mutations

May 30, 2023 · 4 shares · 393 followers View post →

Laure Chotel

@LaureChotel · X

RT @CrozrX: RAS-targeted cancer therapy: Advances in drugging specific mutations

May 29, 2023 · 4 shares · 123 followers View post →

Molly20256

@Molly20186 · X

RT @CrozrX: RAS-targeted cancer therapy: Advances in drugging specific mutations

May 29, 2023 · 4 shares · 83 followers View post →

Daniel Gerlach

@gerlach_d · X

RT @CrozrX: RAS-targeted cancer therapy: Advances in drugging specific mutations

May 29, 2023 · 4 shares · 1,716 followers View post →

GHF Ph.D

@forbesygordi · X

Excellent review on the past, present and future of RASi. https://t.co/EvG3jXVEPL

May 29, 2023 · 1 like · 155 followers View post →

CrozrX

@CrozrX · X

RAS-targeted cancer therapy: Advances in drugging specific mutations

May 28, 2023 · 9 likes · 4 shares · 979 followers View post →

RAS-targeted cancer therapy: Advances in drugging specific mutations.

Mentions per month

Where it's discussed

What people are saying

Abstract in brief

Top posts

All mentions

Advances in RAS-Targeted Cancer Therapies and Mutation Inhibition